Hypertrophic Cardiomyopathy (HCM)

September 23, 2021

Black HCM patients were more likely than White HCM patients to have mid-ventricular obstruction, according to recently reported findings.

September 09, 2021

Japanese researchers say their study suggests that atrial fibrillation may trigger adverse events in HCM patients.

August 19, 2021

At a placeholder price of $75,000 per year for mavacamten used along with standard first-line treatment for symptomatic obstructive hypertrophic cardiomyopathy was above the threshold of $150,000 per QALY.

August 18, 2021

Positive trial results were reported in The Lancet last year. The FDA is scheduled (the PDUFA date) to make a decision on the application for approval early next year.

August 17, 2021

Hypertrophic cardiomyopathy or HCM is one of the most common genetic or congenital cardiac diseases. Affecting as many as 1 in 500 people, HCM is characterized by large increases in cardiac mass, in particular, left ventricular mass. Such enlargement predisposes seemingly healthy sufferers to sudden death at young ages.